CP
CRDF icon

Castleview Partners’s Cardiff Oncology CRDF Stock Holding History

Castleview Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,995
Closed -$44.1K – 181
2025
Q2 		$44.1K Sell
13,995
-470
-3% -$1.43K 0.03% 172
2025
Q1 		$45.4K Buy
+14,465
New +$57.2K 0.03% 176

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Castleview Partners's CRDF Position: Q3 2025 in Review

Castleview Partners sold out of Cardiff Oncology (CRDF) in Q3 2025, closing a stake of 13,995 shares — an estimated $44.1K sold.

Castleview Partners first reported a position in CRDF in Q1 2025 and held it in 2 quarters. The position peaked at $45.4K in Q1 2025. 112 funds tracked by Wall St. Rank hold CRDF as of Q3 2025.

  • Castleview Partners reported no remaining Cardiff Oncology position as of Q3 2025 after selling out during the quarter.
  • Castleview Partners sold 13,995 Cardiff Oncology shares in Q3 2025, an estimated $44.1K.
  • Castleview Partners first reported a position in Cardiff Oncology in Q1 2025 and held it in 2 quarters.
  • Castleview Partners's Cardiff Oncology position peaked at $45.4K in Q1 2025.
  • 112 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2025.

Based on Castleview Partners's 13F filing for Q3 2025, filed 10 Oct 2025.